All In Biotech

Drug Trial Radar · NCT07297654

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment

First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 27, 2026

Primary completion

May 2028

Study completion May 2028

Sponsor

Lead sponsor
National Cancer Center, KoreaGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Asan Medical Center; Seoul National University Hospital; Seoul National University Bundang Hospital; Samsung Medical Center; Hanyang University Guri Hospital
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.

Conditions

  • Advanced Hepatocellular Carcinoma

Interventions

  • LenvatinibDrug

    Lenvatinib will be administered orally at a dose of 8 mg once daily at the same time each day, with or without food (regardless of body weight). For participants with a baseline body weight ≥60 kg who tolerate lenvatinib at 8 mg once daily (i.e., experiencing only Grade 1 or lower adverse events) and have maintained this dose for at least 2 weeks, the daily dose of lenvatinib may be increased to 12 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center

    Goyang-si, South Korea · Recruiting

  • Hanyang University Guri Hospital

    Guri-si, South Korea · Not yet recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.